Pauline Howell to Cost-Benefit Analysis
This is a "connection" page, showing publications Pauline Howell has written about Cost-Benefit Analysis.
Connection Strength
0,210
-
Patient and provider costs of the new BPaL regimen for drug-resistant tuberculosis treatment in South Africa: A cost-effectiveness analysis. PLoS One. 2024; 19(10):e0309034.
Score: 0,210